Josep-Maria Ribera, MD, PhD, Germans Trias i Pujol University Hospital, Barcelona, Spain, discusses the latest developments in newly diagnosed and relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) research. Specifically, Prof. Ribera explores evolving immunotherapy approaches and measurable residual disease (MRD) assessment. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

свернуть